Callan Family Office LLC Acquires New Position in Natera, Inc. (NASDAQ:NTRA)

Callan Family Office LLC acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,809 shares of the medical research company’s stock, valued at approximately $286,000.

A number of other large investors also recently modified their holdings of the company. Chartwell Investment Partners LLC increased its stake in Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the period. Cerity Partners LLC increased its stake in Natera by 27.0% in the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after purchasing an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Natera in the 3rd quarter worth approximately $385,000. Everence Capital Management Inc. purchased a new position in Natera in the 4th quarter worth approximately $573,000. Finally, Alpha DNA Investment Management LLC purchased a new position in Natera in the 3rd quarter worth approximately $505,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Trading Down 5.7 %

Natera stock opened at $132.63 on Tuesday. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00. The company has a market capitalization of $17.93 billion, a price-to-earnings ratio of -75.36 and a beta of 1.80. The business’s fifty day simple moving average is $165.61 and its two-hundred day simple moving average is $148.09. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. As a group, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 87,272 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80. Following the sale, the chief executive officer now directly owns 203,354 shares of the company’s stock, valued at approximately $29,160,963.60. This represents a 30.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Solomon Moshkevich sold 6,000 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total value of $859,740.00. Following the sale, the insider now directly owns 143,768 shares in the company, valued at $20,600,516.72. This trade represents a 4.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 294,946 shares of company stock valued at $47,212,702. Insiders own 7.60% of the company’s stock.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of analyst reports. Piper Sandler lifted their price target on Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. JPMorgan Chase & Co. boosted their target price on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Canaccord Genuity Group reissued a “buy” rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Craig Hallum boosted their target price on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $173.56.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.